In Silico Design and Optimisation of Phytoalexin Resveratrol Polyphenolic Analogs as Inhibitors of Histone Acetyltransferase for the Management of Tumor Growth

Journal Title: UNKNOWN - Year 2018, Vol 8, Issue 8

Abstract

Cancer cells are known to be more susceptible to deoxyribonucleic acid (DNA) damage than normal ones due to their genetic instability. The post-translation modification of histones plays a crucial role in chromatin regulation, influencing gene expression, DNA replication and repair. Histone acetyl transferases (HAT) are enzymes that acetylate histones, often resulting in increased gene expression and cellular proliferation. Consequently, modulators of HAT have the potential to be promising chemotherapeutic agents, due to their ability to restrict neoplastic cellular proliferation and DNA repair.Literature suggests that resveratrol’s anti-cancerous effects are a result of its inhibition of histone deacetylases, however, despite the promising efficacy of the anti-proliferative effects documented in both in vitro and in vivo studies, the precise mechanism of action of resveratrol’s capability to suppress tumor growth is still under investigation. This study has consequently considered resveratrol from a different perspective, and has used this seemingly applicable molecule as a potential ligand for the p300-HAT enzyme and thus, has investigated its potential to modulate the p300-HAT ligand binding pocket (p300-HAT_LBP), a protein which is implicated in the epigenetic evolution of many epithelial and haematological malignancies. Superior novel inhibitors were designed through a dual-methodology, comprising of de novo and virtual screening drug design approaches.Two structures, identified through virtual screening, specifically, Chembridge_5190757 and IBS-STOCK1N-57915, and one de novo generated structure, Result_133, that satisfied all measured parameters of Lipinski rule compliance, high ligand binding affinity and predicted safety upon oral administration, were identified for optimisation and in vitrovalidation, on the premise that they hold promise as clinically useful anti-neoplastic agen

Authors and Affiliations

Rebecca Hammet, Clarie Shoemak

Keywords

Related Articles

In Vitro Neuro-Protective Studies of Phyto-Compounds from Azadirachta indica, Centella asiatica and Gloriosa superba

The test substances quercitin dehydrate, asiatic acid and colchicine were evaluated for its in vitro neuro-protective activity against Hydrogen peroxide induced toxicity in HEK-293-(Human embryoni...

Sildenafil (ViagraTM): Synthesis Step by Step and its Pharmaceutical Importance in Diabetic Patients with Erectile Dysfunction

Objective: Sildenafil is a selective inhibitor of phosphodiesterase 5 (PDE5) and is the first agent with this mode of action for the treatment of male erectile dysfunction. There has recently been an explosion of interes...

EGFR Tyrosine Kinase Targeted In Silico Design and Synthesis of Novel Quinazoline Derivatives

Quinazolines are medicinally important as anti-convulsant, anti-cancer, anti-microbial, and anti-tubercular properties etc. They target epidermal growth factor receptors on tumor cells. This work is aimed to synthesize a...

Encouraging Effects of Ethacrynic Acid Derivatives Possessing a Privileged α, β-Unsaturated Carbonyl Structure Scaffold

α, β-unsaturated carbonyl unit has remarkable utility in the development of biologically active and therapeutically relevant compounds in medicinal chemistry. In recent years, a number of Ethacrynic acid (EA...

Synthesis and Antioxidant Activity of Mixed Ligand Complex of Quercetin and Aspartic Acid with Cobalt(II)

Mixed ligand complexes are widely used in the field of pharmaceutical science due to their curing nature to various diseases. The present study was aimed to synthesize and explore the antioxi...

Download PDF file
  • EP ID EP673133
  • DOI -
  • Views 47
  • Downloads 0

How To Cite

Rebecca Hammet, Clarie Shoemak (2018). In Silico Design and Optimisation of Phytoalexin Resveratrol Polyphenolic Analogs as Inhibitors of Histone Acetyltransferase for the Management of Tumor Growth. UNKNOWN, 8(8), 242-249. https://europub.co.uk/articles/-A-673133